Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive, and irreversible lung disease characterized by fibrotic tissue replacing normal lung parenchyma, leading to declined pulmonary function and dyspnea.

Macrocycles1 are generally defined as organic compounds with a ring of at least 12 atoms and hold in a chemical space between small molecules and biologics (Figure 1). With the constrained but somewhat flexible conformation, macrocycles often show higher affinity and selectivity to targets compared with their linear analogues. Therefore, macrocycles constitute an excellent tool for the targets which are difficult to modulate by traditional small molecules. With the enormous structural diversity, many of macrocycles display a wide range of functional capability and remarkable biological activities, which makes them as an important modality in drug discovery. More than 60 macrocycles have been approved as drugs by the U.S. Food and Drug Administration. Most of the macrocyclic drugs are natural products or their derivatives. Infectious disease, oncology, autoimmune disorders, and immunosuppressants are the major therapeutic indications of macrocyclic drugs.

The advancement of DNA Encoded Library (DEL) technology has been significant in recent decades. Beyond its conventional role in small molecule drug discovery, its integration into emerging fields has begun to garner increased interest. This can be attributed to its large chemical space, abundant Structure-Signal Relationship (SSR) data, and inherent DNA conjugation properties. In this context, we will explore alternative applications of DEL technology. It is postulated that with the continuous expansion of the DEL field and technological progression, more applications are yet to be unveiled.

As one of the largest and most functionally diverse gene families, kinases have been recognized as key regulators/mediators of biological signaling networks. More than 30% of drug development efforts target these enzymes in the past two decades. As of January 2024, more than 90 small molecule kinase drugs have been approved by the US Food and Drug Administration (FDA), with approximately 200 orally available protein kinase inhibitors in clinical trials. These compounds have had a significant impact on the treatment of both oncological and non-oncological conditions.